In vivo and in situ evaluation of innovative approaches in dentin hypersensitivity treatment

BMC Oral Health

Table 7 Pain intensity scores following thermal testing at different time intervals between and within treatment groups

		PRG	Embrace	Duraphat	p-value
Baseline	Mean [± SD]	8.8^aA [± 1.0]	9.0^aA [± 1.0]	9.0^aA [± 0.8]	0.837
Baseline	Median (Range)	9 (7–10)	9 (7–10)	9 (8–10)	0.837
3 min	Mean [± SD]	0.1^aB [± 0.4]	6.3^bB [± 0.8]	6.7^bB [± 0.8]	< 0.001*
3 min	Median (Range)	0 (0–1)	6 (5–8)	7 (6–9)	< 0.001*
2 weeks	Mean [± SD]	0.3^aB [± 0.5]	2.4^bC [± 0.8]	3.6^cC [± 0.7]	< 0.001*
2 weeks	Median (Range)	0 (0–1)	2 (1–4)	3 (3–5)	< 0.001*
4 weeks	Mean [± SD]	0.6^aB [± 0.5]	2.6^bC [± 0.9]	4.4^cCD [± 0.7]	< 0.001*
4 weeks	Median (Range)	1 (0–1)	2 (1–5)	4 (3–6)	< 0.001*
8 weeks	Mean [± SD]	0.6^aB [± 0.5]	3.5^bD [± 0.6]	5.4^cD [± 0.7]	< 0.001*
8 weeks	Median (Range)	1 (0–1)	3 (3–5)	5 (4–6)	< 0.001*
	p-value	< 0.001*	< 0.001*	< 0.001*

* Statistically Significant at p = 0.05
** Values are presented as mean [± SD] and median (range). Statistical significance for between-group comparisons (same row) was determined using Kruskal-Wallis test followed by Dunn’s post hoc test for pairwise comparisons. Within-group comparisons (same column) were analyzed using Friedman test followed by Dunn’s post hoc test for pairwise comparisons
*** Different lowercase letters (a, b, c) indicate significant differences between groups at each time point
**** Different uppercase letters (A, B, C, D) indicate significant differences within groups over time

ISSN: 1472-6831